<DOC>
	<DOCNO>NCT01510184</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Zevalin compare observation alone patient PET-negative complete remission first-line R-CHOP R-CHOP like therapy .</brief_summary>
	<brief_title>Study Zevalin Versus Observation Patients Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma PET-negative Complete Remission After R-CHOP R-CHOP-like Therapy</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patient 60years age old time randomization 2 . Histologically confirm Ann Arbor stage II , III , IV DLBCL ; FCL Grade 3B accord REAL/WHO classification ( initial diagnosis make prior start RCHOP therapy ) . Results pre RCHOP marrow shall available review . 3 . Local pathology review confirm DLBCL diagnosis CD20 positivity , evidence DLBCL bone marrow upon confirmation CR . 4 . A paraffin block original slide available confirmatory pathology review . Patients may randomize base local pathology result . 5 . Ageadjusted IPI 1 , 2 , 3 . The age adjust IPI define one point LDH &gt; upper limit normal ( ULN ) ; Stage III IV ; Karnofsky performance status &lt; 80 % WHO/ECOG performance status &gt; 1 . 6 . Firstline treatment DLBCL must 6 cycle standard RCHOP21 , RCHOP14 DAEPOCHR chemotherapy . Patients receive prephase therapy purpose improve performance status prior initiate RCHOP eligible . ( See CRF Manual clarification ) . 7 . Complete remission ( CR ) accord International Workshop Response Criteria NHL describe Cheson et al ( Appendix 2 ) . firstline treatment . CT scan chest , abdomen , pelvis , neck ( applicable ) must perform within 6 week last dose last course chemotherapy . Applicability neck CT mean patient involvement neck region palpation / physical examination first diagnosis . 8 . A negative FDGPET scan confirm complete response , negative define score 13 Deauville 5point scale ( Appendix 3 ) use quantify radionucleotide density PET scan determine locally ( Morschhauser 200735 ) . 9 . Bone marrow cellularity great 15 % , evidence myelodysplasia morphologically evidence involvement lymphoma either pre RCHOP marrow repeat assessment preZevalin . After complete Rchemotherapy , repeat marrow require patient randomized Zevalin arm . 10 . A WHO/ECOG performance status 0 , 1 2 . 11 . Adequate hematopoietic function : Absolute neutrophil count ( ANC ) ≥ 1.0 x 109/L , Hemoglobin ( Hgb ) ≥ 9 g/dL , Platelets ≥ 100 x 109/L . 12 . Life expectancy 6 month longer 13 . Written inform consent obtain accord local guideline 1 . Presence malignancy history prior malignancy within 5 year study entry . Within 5 year , patient treat Stage I II cancer eligible provided life expectancy &gt; 5 year ( See CRF Manual clarification ) . The 5year exclusion rule apply tonon melanoma skin tumor situ cervical cancer . 2 . Prior radioimmunotherapy , include radiation therapy NHL , NHL therapy . 3 . Presence primary gastric , central nervous system ( CNS ) , testicular lymphoma first diagnosis . 4 . Histological transformation lowgrade NHL . 5 . Active hepatitis B C. ( See CRF completion manual ) 6 . Known history HIV infection . 7 . Abnormal liver function : total bilirubin &gt; 2 × ULN unless secondary Gilbert disease . 8 . Abnormal renal function : serum creatinine &gt; 2.0 × ULN . 9 . Nonrecovery toxic effect chemotherapy &lt; grade 2 , interfere Zevalin treatment . 10 . Known hypersensitivity murine chimeric antibody proteins 11 . GCSF GMCSF therapy within 4 week prior Zevalin observation . 12 . Concurrent severe and/or medically uncontrolled disease ( e.g . uncontrolled diabetes , congestive heart failure , myocardial infarction within 6 month study , unstable uncontrolled hypertension , chronic renal disease , active uncontrolled infection ) could compromise participation study . 13 . Treatment investigational drug le 4 week prior Zevalin observation . 14 . Major surgery le 4 week prior Zevalin start observation . 15 . Concurrent systemic corticosteroid use reason except premedication case know suspected allergy contrast medium premedication potential side effect rituximab treatment . Patients chronic dose prednisone medical condition ( e.g . Asthma autoimmune disease ) less equal 20mg daily , stable 4 week , permissible . 16 . Unwillingness inability comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>